Overtreatment in adults with epilepsy

Epilepsy Research

Volumn 52, Issue 1, 2002, Pages 43-52

  Deckers, Charles L P ^a,b  

^a STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adults; Adverse effects; Combination therapy; Drug load; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE;

CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; EPILEPSY; MEDICAL DECISION MAKING; MONOTHERAPY; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RISK; SCLEROSIS; TITRIMETRY;

ADULT; ANTICONVULSANTS; COMBINED MODALITY THERAPY; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSY; HUMANS; OVERDOSE; PHARMACOEPIDEMIOLOGY; PROGNOSIS; TIME FACTORS;

EID: 0036851024     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(02)00184-5     Document Type: Conference Paper

References (63)

1. Albright P., Bruni J. Reduction of polypharmacy in epileptic patients. Arch. Neurol. 42:1985;797-799.
2. Arroyo S., Brodie M.J., Avanzini G., Baumgartner G., Chiron C., Dulac O., et al. Is refractory epilepsy preventable? Epilepsia. 43:2002;437-444.
3. Barcs G., Walker E.B., Elger C.E., Scaramelli A., Stefan H., Sturm Y., et al. Oxcarbazepine placebo-controlled dose-ranging trial in refractory partial epilepsy. Epilepsia. 41:2000;1597-1607.
4. Beghi E., Sasanelli F., Spagnoli A., Tognoni G. Quality of care of epilepsy in Italy: multi-hospital survey of diagnosis and treatment of 1104 epileptic patients. Epilepsia. 23:1982;133-148.
5. The Group for the Study of Epilepsy in General Practice, Beghi E., Monticelli M.L., Monza G., Sessa A., Zarrelli M. Antiepileptic drugs as 'tracers' of disease; a calculation of the prevalence of epilepsy through an analysis of drug consumption. Neuroepidemiology. 10:1991;33-41.
6. Brodie M.J., Richens A., Yuen A.W. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet. 345:1995;476-479.
7. Brodie M.J., Overstall P.W., Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res. 37:1999;81-87.
8. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., Leppik I., et al. Levetiracetam for partial seizures: results of a double-blind, randomized, clinical trial. Neurology. 55:2000;236-242.
9. Chappel B., Hall W.W. Managing epilepsy in general practice: the dissemination and uptake of a free audit package, and collated results from 12 practices in England and Wales. Seizure. 6:1997;9-12.
10. Chen L.C., Chen Y.F., Yang L.L., Chou M.H., Lin M.F. Drug utilization pattern of antiepileptic drugs and traditional Chinese medicines in a general hospital in Taiwan - a pharmaco-epidemiologic study. J. Clin. Pharm. Ther. 25:2000;125-129.
11. Collaborative Group for the Study of Epilepsy, 1992. Prognosis of epilepsy in newly referred patients: A multicenter prospective study of the effects of monotherapy on the long-term course of epilepsy. Epilepsia 33, 45-51.
12. Deckers C.L.P. The place of combination therapy in the early treatment of epilepsy. CNS Drugs. 16:2002;155-163.
13. Deckers C.L.P., Hekster Y.A., Keyser A., Lammers M.W., Meinardi H., Renier W.O. Detection of adverse effects in epilepsy therapy: wait and see or go for it? Acta Neurol. Scand. 95:1997;248-252.
14. Deckers C.L.P., Hekster Y.A., Keyser A., Meinardi H., Renier W.O. Drug load in clinical trials: a neglected factor. Clin. Pharmacol. Ther. 62:1997;592-595.
15. Deckers C.L.P., Czuczwar S.J., Hekster Y.A., Keyser A., Kubova H., Meinardi H., et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 41:2000;1364-1374.
16. Deckers C.L.P., Hekster Y.A., Keyser A., van Lier H.J.J., Meinardi H., Renier W.O. Monotherapy versus polytherapy for epilepsy: a multi-center double-blind randomized study. Epilepsia. 42:2001;1387-1394.
17. De-Deyn P.P., Mol L., de-Ridder-Vanderdeelen P., Eerdekens M. An open multicentre prospective study of the effects of monotherapy with controlled-release carbamazepine on newly diagnosed generalized tonic-clonic seizures. Seizure. 3:1994;235-238.
18. Dlugos D.J. The early identification of candidates for epilepsy surgery. Arch. Neurol. 58:2001;1543-1546.
19. Faught E., Wilder B.J., Ramsay R.E., Reife R.A., Kramer L.D., Pledger G.W., et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200- 400- and 600-mg daily dosages. Neurology. 46:1996;1684-1690.
20. Gerety M.B., Cornell J.E., Plichta D.T., Eimer M. Adverse events related to drugs and drug withdrawal in nursing home residents. Am. Geriatr. Soc. 41:1993;1326-1332.
21. Giuliani G., Terziani S., Senigaglia A.R., Luccioni G., Foschi N., Maffei C. Epilepsy in an italian community as assessed by a survey for prescriptions of antiepileptic drugs: epidemiology and patterns of care. Acta Neurol. Scand. 85:1992;23-31.
22. Hakkarainen H. Carbamazepine vs. diphenylhydantoin vs. their combination in adult epilepsy. Neurology. 30:1980;354.
23. Jacoby A., Graham-Jones S., Baker G., Ratoff L., Heyes J., Dewey M., et al. A general practice records audit of the process of care for people with epilepsy. Br. J. Gen. Pract. 46:1996;595-599.
24. Kanner A.M., Frey M. Do valproic acid and lamotrigine have a synergistic antiepileptic effect? Epilepsia. 40:(Suppl. 2):1999;284.
25. Krakow K., Walker M., Otoul C., Sander J.W.A.S. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology. 56:2001;1772-1774.
26. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 342:2000;314-319.
27. Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on? Seizure. 9:2000;464-468.
28. Kwan P., Brodie M.J. Effectiveness of first antiepileptic drug. Epilepsia. 42:2001;1255-1260.
29. Lackner T.E. Strategies for optimizing antiepileptic drug therapy in elderly people. Pharmacotherapy. 22:2002;329-364.
30. Lackner T.E., Cloyd J.C., Thomas L.W., Leppik I.E. Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use. Epilepsia. 39:1998;1083-1087.
31. Lammers M.W., Hekster Y.A., Keyser A., Meinardi H., Renier W.O., van-Lier H. Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment. Epilepsia. 36:1995;440-446.
32. Lammers M.W., Hekster Y.A., Keyser A., Meinardi H., Renier W.O., Herings R.M.C. Use of anti-epileptic drugs in a community-dwelling population. Neurology. 46:1996;62-67.
33. Lhatoo S.D., Wong I.C.K., Polizzi G., Sander J.W.A.S. Long-term retention rates of lamotrigine, gabapentin and topiramate in chronic epilepsy. Epilepsia. 41:2000;1592-1596.
34. Lhatoo S.D., Sander J.W.A.S., Shorvon S.D. The dynamics of drug treatment in epilepsy: an observational study in an unselected population based cohort with newly diagnosed epilepsy followed up prospectively over 11-14 years. J. Neurol. Neurosurg. Psychiatry. 71:2001;632-637.
35. Matsuo F., Bergen D., Faught E., Messenheimer J.A., Dren A.T., Rudd G.D., et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology. 43:1993;2284-2291.
36. Mattson R.H., Cramer J.A., Collins J.F. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N. Engl. J. Med. 327:1992;765-771.
37. Mattson R.H., Cramer J.A. The choice of antiepileptic drugs in focal epilepsy. Wyllie E., The Treatment of Epilepsy. Principles and Practice. 1st ed. 1993;817-823 Lea & Febiger, Philadelphia.
38. The Department of Veterans Affairs Epilepsy Cooperative Studies no. 118 and no. 264 Group, Mattson R.H., Cramer J.A., Collins J.F. Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures. Neurology. 47:1996;68-76.
39. McLean M.J., Morrell M.J., Willmore L.J., Privitera M.D., Faught R.E., Magnus-Miller L., et al. Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. Epilepsia. 40:1999;965-972.
40. Morrell M.J., McLean M.J., Willmore L.J., Privitera M.D., Faught R.E., Holmes G.L., et al. Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. Seizure. 9:2000;241-248.
41. Muir T.M., Bradley A., Wood S.F., Murray G.D., Brodie M.J. An audit of treated epilepsy in Glasgow. West of Scotland Epilepsy Research Group. Seizure. 5:1996;41-46.
42. Nieto-Barrera M., Brozmanova M., Capovilla G., Christe W., Pedersen B., Kane K., et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res. 46:2001;145-155.
43. Reunanen M., Dam M., Yuen A.W.C. A randomized open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res. 23:1996;149-155.
44. Reynolds E.H., Chadwick D.W., Shorvon S.D. One drug (phenytoin) for treatment of epilepsy. Lancet. 1:1976;923-926.
45. Richens A., Davidson D.L., Cartlidge N.E., Easter D.J. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group. J. Neurol. Neurosurg. Psychiatry. 57:1994;682-687.
46. Rochat P., Hallas J., Gaist D., Friis M.L. Antiepileptic drug utilization: a Danish prescription database analysis. Acta Neurol. Scand. 104:2001;6-11.
47. Rosenfeld W.E., Sachdeo R.C., Faught R.E., Privitera M. Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizures: retrospective study of open-label treatment. Epilepsia. 38:(Suppl. 1):1997;34-36.
48. Schmidt D. Reduction of two-drug therapy in intractable epilepsy. Epilepsia. 24:1983;368-376.
49. Shinnar S., Berg A.T. Does antiepileptic drug therapy prevent the development of 'chronic' epilepsy? Epilepsia. 37:1996;701.
50. Shorvon S. Handbook of Epilepsy Treatment. 2000;Blackwell Science, Oxford, pp. 44.
51. Shorvon S.D., Reynolds E.H. Unnecessary polypharmacy for epilepsy. Br. Med. J. 1:1977;1635-1637.
52. Shorvon S.D., Chadwick D., Galbraith A.W., Reynolds E.H. One drug for epilepsy. Br. Med. J. 1:1978;474-476.
53. Shorvon S.D., Reynolds E.H. Reduction in polypharmacy for epilepsy. Br. Med. J. 2:1979;1023-1025.
54. Steiner T.J., Dellaportas C.I., Findley L.J., Gross M., Gibberd F.B., Perkin G.D., et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia. 40:1999;601-607.
55. Tanganelli P., Regesta G. Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study. Epilepsy Res. 25:1996;257-262.
56. Thompson P.J., Trimble M.R. Anticonvulsant drugs and cognitive functions. Epilepsia. 23:1982;531-544.
57. Tiffin P.A., Perini A.F. The use of antiepileptic drugs in learning disabled people with epilepsy: an audit of adult in-patients in a treatment and continuing care service. Seizure. 10:2001;500-504.
58. Tobias E.S., Brodie A.F., Brodie M.J. An outcome audit at the epilepsy clinic: results from 1000 consecutive referrals. Seizure. 3:1994;37-43.
59. Uhtman M., Rowan J., Ahmann P.A., Leppik I.E., Schacter S.C., Sommerville K.W., et al. Tiagabine for complex partial seizures. Arch. Neurol. 55:1998;56-62.
60. Walker J.E., Koon P. Carbamazepine versus valproate versus combined therapy for refractory partial complex seizures with secondary generalization. Epilepsia. 29:1988;693.
61. WHO Collaborating Centre for Drugs Statistics Methodology and Nordic Council on Medicines, 1996. Guidelines for DDD and ATC Classification. WHO, Oslo.
62. Wong I.C.K., Mawer G.E., Sander J.W.A.S. Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom. Epilepsia. 42:2001;237-244.
63. Wong I.C.K., Mawer G.E., Sander J.W.A.S., Lhatoo S.D. A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy. Epilepsia. 42:2001;1354-1358.